# Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

> **NCT06094920** · PHASE4 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 12 (actual)

## Conditions studied

- Diabetes Mellitus Type 2 With Proteinuria
- Diabetes Mellitus, Type 2
- Diabetes Mellitus
- Diabetes
- Diabetes Complications
- Albuminuria
- Chronic Kidney Diseases
- Chronic Kidney Disease Due to Type 2 Diabetes Mellitus
- Chronic Kidney Disease stage3
- Chronic Kidney Disease stage4
- CKD
- CKD Stage 3
- CKD Stage 4

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Finerenone
- **DEVICE:** Withings BPM Connect
- **DEVICE:** Withings Body
- **DIAGNOSTIC_TEST:** PeeSpot Urine Collection Device
- **DIAGNOSTIC_TEST:** Hem-Col Capillary Blood Collection Device
- **BEHAVIORAL:** Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies

## Key facts

- **NCT ID:** NCT06094920
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-29
- **Primary completion:** 2025-09-24
- **Final completion:** 2025-09-24
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094920, "Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06094920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*